Bayer AG acquires Icon Genetics
Clients Bayer AG
Jones Day advised Bayer AG in the acquisition by its subsidiary Bayer Innovation GmbH of Icon Genetics AG from its founders and certain mostly state-owned venture capital funds. Icon Genetics discovers innovative methods for the development and use of engineered plants. Bayer Innovation evaluates and develops new fields of business for the Bayer Group that are in line with Bayer's core competencies of health care, nutrition and high-tech materials and complement its current key areas of innovation and business. Bayer and Icon Genetics had already cooperated on research projects prior to the transaction.